Skip to content

Press

Surge receives $32 million in series B • Chemical & Engineering News Media Coverage | 23 July 2023
SURGE – US startup bags $32 million to blend cancer surgery and immunotherapy • Outsourcing Pharma Media Coverage | 20 July 2023
SURGE Therapeutics secures $32m to advance intraoperative immunotherapy • NS Healthcare Media Coverage | 20 July 2023
Immunotherapy during surgery? Surge Therapeutics nabs $32M to expand clinical plans after first dosing • Endpoints Media Coverage | 19 July 2023
SURGE – This Startup Just Raised $32 Million To Keep Cancers From Recurring After Surgery • Forbes Media Coverage | 19 July 2023
Surge Therapeutics Raises $32M in Series B Financing • FinSMEs Media Coverage | 19 July 2023
July 19 Quick Takes: Surge Therapeutics Inc. raised a $32 million series B round • Biocentury Media Coverage | 19 July 2023
Recode Therapeutics Appoints Erica Jefferson as Senior Vice President of Corporate Affairs Press Releases | 10 July 2023
ReCode–a New Contestant in the mRNA Race • Biospace Media Coverage | 22 May 2023
Nido Bio: treating neurodegeneration with small molecules • Biocentury Media Coverage | 17 May 2023